GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
C/NL/06/01_001 Suntory Flowers Limited Application for renewal of consent for marketing approval under Directive 2001/18/EC (Event FLORIGENE®Moonaqua™(FLO-4Ø689-6)) 09-11-2018 Vergunning verleend
IM-MV 18-013_000 UMCG A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) 01-07-2019 Vergunning verleend
IM-MV 19-002_000 Universitair Medisch Centrum Utrecht Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells 02-07-2019 Vergunning verleend
IM-MV 19-007_000 Het Nederlands Kanker Instituut An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma and further clinical studies with VXM01 in patients with solid malignancies 23-07-2019 Vergunning verleend
IM-MV 19-008_000 Het Nederlands Kanker Instituut Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK33777794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers Ontwerpbesluit genomen
IM-MV 19-010_000 Universitair Medisch Centrum Utrecht A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) Ontwerpbesluit genomen
IM-MV 19-011_000 Erasmus MC Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells Ontwerpbesluit genomen
IM-MV 19-012_000 VU medisch centrum Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumor cells Ontwerpbesluit genomen
IM-MV 19-013_000 LUMC A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) Ontwerpbesluit genomen
IM-MV 19-014_000 UMCG Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells Ontwerpbesluit genomen